On Monday, 10x Genomics Inc (NASDAQ: TXG) was -4.69% drop from the session before settling in for the closing price of $9.16. A 52-week range for TXG has been $8.92 – $37.86.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 21.90% over the past five years. When this article was written, the company’s average yearly earnings per share was at 0.83%. With a float of $100.79 million, this company’s outstanding shares have now reached $108.24 million.
Let’s look at the performance matrix of the company that is accounted for 1306 employees. In terms of profitability, gross margin is 68.73%, operating margin of -31.51%, and the pretax margin is -29.09%.
10x Genomics Inc (TXG) Insider Updates
Also, it is sometimes useful to examine the sentiment of large-scale investors toward 10x Genomics Inc stocks. The insider ownership of 10x Genomics Inc is 17.59%, while institutional ownership is 79.43%. The most recent insider transaction that took place on Feb 28 ’25, was worth 84,393. In this transaction Chief Executive Officer of this company sold 7,942 shares at a rate of $10.63, taking the stock ownership to the 871,540 shares. Before that another transaction happened on Feb 28 ’25, when Company’s Director, CEO proposed sale 7,942 for $10.57, making the entire transaction worth $83,947.
10x Genomics Inc (TXG) Performance Highlights and Predictions
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.14 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 0.83% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 17.16% during the next five years compared to -36.10% drop over the previous five years of trading.
10x Genomics Inc (NASDAQ: TXG) Trading Performance Indicators
You can see what 10x Genomics Inc (TXG) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 4.26. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 1.75.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.52, a number that is poised to hit -0.47 in the next quarter and is forecasted to reach -1.16 in one year’s time.
Technical Analysis of 10x Genomics Inc (TXG)
10x Genomics Inc (NASDAQ: TXG) saw its 5-day average volume 3.02 million, a positive change from its year-to-date volume of 2.84 million. As of the previous 9 days, the stock’s Stochastic %D was 7.47%. Additionally, its Average True Range was 0.69.
During the past 100 days, 10x Genomics Inc’s (TXG) raw stochastic average was set at 0.63%, which indicates a significant decrease from 2.60% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 60.55% in the past 14 days, which was lower than the 66.96% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $12.05, while its 200-day Moving Average is $16.64. Nevertheless, the first resistance level for the watch stands at $8.92 in the near term. At $9.12, the stock is likely to face the second major resistance level. The third major resistance level sits at $9.24. If the price goes on to break the first support level at $8.60, it is likely to go to the next support level at $8.48. Assuming the price breaks the second support level, the third support level stands at $8.28.
10x Genomics Inc (NASDAQ: TXG) Key Stats
There are 122,302K outstanding shares of the company, which has a market capitalization of 1.07 billion. As of now, sales total 610,790 K while income totals -182,630 K. Its latest quarter income was 165,020 K while its last quarter net income were -49,030 K.
